Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells.

Saved in:
Bibliographic Details
Title: Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells.
Authors: Labaf M; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Mathematics, University of Massachusetts Boston, Boston, Massachusetts.; Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts., Han W; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Biology, University of Massachusetts Boston, Boston, Massachusetts.; Human Biology Division, Fred Hutchinson Cancer Center, Washington., Zhang S; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Biology, University of Massachusetts Boston, Boston, Massachusetts., Liu M; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Biology, University of Massachusetts Boston, Boston, Massachusetts., Patten ND; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Biology, University of Massachusetts Boston, Boston, Massachusetts., Li M; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Biology, University of Massachusetts Boston, Boston, Massachusetts.; Division of Urology, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Patalano S; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Biology, University of Massachusetts Boston, Boston, Massachusetts., Macoska JA; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Biology, University of Massachusetts Boston, Boston, Massachusetts., Balk SP; Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts., Han D; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Biology, University of Massachusetts Boston, Boston, Massachusetts., Zarringhalam K; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts., Cai C; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.; Department of Biology, University of Massachusetts Boston, Boston, Massachusetts.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2025 May 02; Vol. 24 (5), pp. 772-783.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-24-0716